Literature DB >> 26073491

ErbB small molecule tyrosine kinase inhibitor (TKI) induced diarrhoea: Chloride secretion as a mechanistic hypothesis.

Ysabella Z A Van Sebille1, Rachel J Gibson2, Hannah R Wardill3, Joanne M Bowen4.   

Abstract

Diarrhoea is a common, debilitating and potentially life threatening toxicity of many cancer therapies. While the mechanisms of diarrhoea induced by traditional chemotherapy have been the focus of much research, the mechanism(s) of diarrhoea induced by small molecule ErbB TKI, have received relatively little attention. Given the increasing use of small molecule ErbB TKIs, identifying this mechanism is key to optimal cancer care. This paper critically reviews the literature and forms a hypothesis that diarrhoea induced by small molecule ErbB TKIs is driven by intestinal chloride secretion based on the negative regulation of chloride secretion by ErbB receptors being disrupted by tyrosine kinase inhibition.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Chloride secretion; Diarrhoea; ErbB (EGFR, HER); Mucositis; TKI

Mesh:

Substances:

Year:  2015        PMID: 26073491     DOI: 10.1016/j.ctrv.2015.05.011

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN: 0305-7372            Impact factor:   12.111


  14 in total

Review 1.  Neratinib in HER-2-positive breast cancer: results to date and clinical usefulness.

Authors:  Arlene Chan
Journal:  Ther Adv Med Oncol       Date:  2016-07-10       Impact factor: 8.168

2.  Pathophysiology of neratinib-induced diarrhea in male and female rats: microbial alterations a potential determinant.

Authors:  Kate R Secombe; Imogen A Ball; Joseph Shirren; Anthony D Wignall; Dorothy M Keefe; Joanne M Bowen
Journal:  Breast Cancer       Date:  2020-07-18       Impact factor: 4.239

Review 3.  Mechanism, safety and efficacy of three tyrosine kinase inhibitors lapatinib, neratinib and pyrotinib in HER2-positive breast cancer.

Authors:  Jun-Cheng Xuhong; Xiao-Wei Qi; Yi Zhang; Jun Jiang
Journal:  Am J Cancer Res       Date:  2019-10-01       Impact factor: 6.166

4.  Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab.

Authors:  S M Swain; A Schneeweiss; L Gianni; J J Gao; A Stein; M Waldron-Lynch; S Heeson; M S Beattie; B Yoo; J Cortes; J Baselga
Journal:  Ann Oncol       Date:  2017-04-01       Impact factor: 32.976

5.  HALT-D: A Phase II Evaluation of Crofelemer for the Prevention and Prophylaxis of Diarrhea in Patients With Breast Cancer on Pertuzumab-Based Regimens.

Authors:  Jennifer J Gao; Ming Tan; Paula R Pohlmann; Sandra M Swain
Journal:  Clin Breast Cancer       Date:  2016-08-27       Impact factor: 3.225

6.  Intestinal epithelial potassium channels and CFTR chloride channels activated in ErbB tyrosine kinase inhibitor diarrhea.

Authors:  Tianying Duan; Onur Cil; Jay R Thiagarajah; Alan S Verkman
Journal:  JCI Insight       Date:  2019-02-21

7.  Neoadjuvant docetaxel with or without carboplatin plus dual HER2 blockade for HER2-positive breast cancer: a retrospective multi-center Chinese study.

Authors:  Minhao Lv; Huihui Guo; Chao Wang; Peiqi Tian; Youzhao Ma; Xiuchun Chen; Suxia Luo
Journal:  Gland Surg       Date:  2020-12

8.  A case of torsades de pointes induced by the third-generation EGFR-TKI, osimertinib combined with moxifloxacin.

Authors:  Shuang Bian; Xiaomiao Tang; Wei Lei
Journal:  BMC Pulm Med       Date:  2020-06-24       Impact factor: 3.317

9.  Potentiation of calcium-activated chloride secretion and barrier dysfunction may underlie EGF receptor tyrosine kinase inhibitor-induced diarrhea.

Authors:  Younjoo Kim; Andrew Quach; Soumita Das; Kim E Barrett
Journal:  Physiol Rep       Date:  2020-07

10.  Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer.

Authors:  Andreas Schneeweiss; Tjoung-Won Park-Simon; Joan Albanell; Ulrik Lassen; Javier Cortés; Veronique Dieras; Marcus May; Christoph Schindler; Frederik Marmé; Juan Miguel Cejalvo; Maria Martinez-Garcia; Iria Gonzalez; Jose Lopez-Martin; Anja Welt; Christelle Levy; Florence Joly; Francesca Michielin; Wolfgang Jacob; Céline Adessi; Annie Moisan; Georgina Meneses-Lorente; Tomas Racek; Ian James; Maurizio Ceppi; Max Hasmann; Martin Weisser; Andrés Cervantes
Journal:  Invest New Drugs       Date:  2018-01-19       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.